Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4623-4626

  Phua, Chee Ee ^a   Bustam, Anita Zarina ^a   Yusof, Mastura Md ^a   Saad, Marniza ^a   Yip, Cheng Har ^a   Taib, Nor Aishah ^a   Ng, Char Hong ^a   Teh, Yew Ching ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Adjuvant chemotherapy; Breast cancer; Febrile neutropaenia (FN); Treatment related death (TRD)

Indexed keywords

EID: 84874016486     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4623     Document Type: Article

References (21)

1. Aapro MS, Bohlius J, Cameron DA, et al (2011). 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy -induced febrile neutropaenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer, 47, 8-32.
2. Aapro MS, Cameron DA, Pettengell, et al (2006). EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropaenia in adult patients with lymphomas and solid tumours. Eur J Cancer, 42, 2433-53.
3. Crawford J, Dale D, Lyman G (2004). Chemotherapy-induced neutropaenia. Risks, consequences and new directions for its management. Cancer, 100, 228-37.
4. Dale DC (2002). Colony-stimulating factors for the management of neutropaenia in cancer patients. Drugs, 62, 1-15.
5. de Naurois J, Novitzky-Basso I, Gill MJ, et al (2010). Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Annals of Oncology, 21, 252-6.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet, 365, 1687-717
7. Ellis P, Barrett-Lee P, Johnson L, et al (2009). Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open label, phase III, randomized controlled trial. Lancet, 373, 1681-92.
8. Ferguson T, Wilcken N, Vagg R, et al (2010). Taxanes for adjuvant treatment of early breast cancer (Review). The Cochrane Cochrane Library, Issue 10.
9. Greil R, Psenak O (2007). Hematopoietic growth factors: ESMO recommendations for the application. Ann Oncol, 18, 89-91.
10. Henderson IC, Berry DA, Demetri GD, et al (2003). Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 21, 976-83.
11. Jones S, Holmes FA, O'Shaughnessy J, et al (2009). Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol, 27, 1177-83.
12. Klastersky J, Awada A, Paesmans M, et al (2011). Febrile neutropaenia: A critical review of the initial management. Critical Reviews in Oncology/Hematology, 78, 185-94.
13. Kuderer NM, Dale DC, Crawford J, et al (2007). Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropaenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol, 25, 3158-67.
14. Lyman GH, Kuderer NM, Djulbegovic B (2002). Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: meta-analysis. Am J Med, 112, 406-11.
15. Madarnas Y, Dent SF, Husain SF, et al (2011). Real world experience with adjuvant FEC_D chemotherapy in four Ontario regional cancer centers. Current Oncology, 18, 119-25.
16. Mamounas EP, Bryant J, Lembersky B, et al (2005). Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-28. J Clin Oncol, 23, 3686-96.
17. Martin M, Pienkowski T, Mackey J, et al (2005). Adjuvant Docetaxel for node positive breast cancer. N Engl J Med, 352, 2302-13.
18. National Comprehensive Cancer Network (2009). Myeloid growth factors. http://www.nccn.org/
19. Phua CE, Bustam AZ Yusof MM, et al (2012). Risk of treatment related death (TRD) with adjuvant chemotherapy for breast cancer: A study in University Malaya Medical Centre (UMMC). J Cancer Therapeutics and Res, 1, 13.
20. Smith TJ, Khatcheressian J, Lyman JH, et al (2006). Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol, 24, 3187-205.
21. Srokowski TP, Fang S, Hortobagyi GN, et al (2009) Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol, 27, 2170-6